Filing Flows › Supernus Pharmaceuticals (SUPN) › ONAPGO revenue
Supernus Pharmaceuticals (SUPN) ONAPGO revenue by quarter
Supernus Pharmaceuticals' ONAPGO revenue was $17.1M in Q3 2026 (third quarter 2026), +26% from Q2 2026. Over the last 6 quarters it ranged from $1.6M (Q2 2025) to $17.1M (Q3 2026).
| Quarter | ONAPGO revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $17.1M | +26% | +151% |
| Q2 2026 | $13.5M | +62% | +745% |
| Q1 2026 | $8.4M | -5% | — |
| Q4 2025 | $8.8M | +30% | — |
| Q3 2025 | $6.8M | +324% | — |
| Q2 2025 | $1.6M | — | — |
Q3 2026 at a glance
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is Supernus Pharmaceuticals' ONAPGO revenue?
Supernus Pharmaceuticals' ONAPGO revenue was $17.1M in Q3 2026 (third quarter 2026), +26% from Q2 2026.
How has Supernus Pharmaceuticals' ONAPGO revenue changed?
Over the last 6 quarters it ranged from $1.6M (Q2 2025) to $17.1M (Q3 2026).
Q3 2026 results → · How Supernus Pharmaceuticals makes money →